Proactive Investors - Run By Investors For Investors

Jury rules for second time on Genus cow semen technology case

The court found that the group had materially breached the confidentiality obligations.
A happy cow
Genus's novel technology is used in sexing bovine semen.

A jury has ruled that animal genetics group Genus plc (LON:GNS) was in infringement of two patents in its court case against Sexing Technologies.

It is the second set of jury verdicts relating to its sexed semen technology.

The court found that the group had materially breached the confidentiality obligations under the 2012 semen sorting agreement between the parties.

It follows Wednesday's verdict that Sexing Technologies had wilfully maintained a monopoly in the US sexed semen market since July 2012.

The jury will now consider a verdict on damages in relation to these matters later this week.

“We expect Genus will incur damages for the infringement of patents and breaching of confidentiality obligations but will benefit from consequences that ST was found to be maintaining a monopoly,” said analysts at Liberum.

“Most important will be implications for the existing contract between the two companies and whether Genus will be free to launch its new technology.”

The broker said investors will need to wait for these additional court decisions for clarity on the financial and strategic implications for Genus and its technology.

Genus’s sexed semen process is a novel technology for sexing bovine semen that does not subject the sperm cells to high pressures and forces. 

Dairy farmers prefer female calves, and the use of gender skewed sexed semen in artificial insemination provides customers with female calves from elite genetic lines. 

View full GNS profile View Profile

Genus Timeline

February 16 2015

Related Articles

Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use